Clinical–alimentary tractGlucagon-Like Peptide 2 Stimulates Glucagon Secretion, Enhances Lipid Absorption, and Inhibits Gastric Acid Secretion in Humans
Section snippets
Study Protocol
The study protocol was approved by the ethics committee of the Ruhr-University of Bochum on March 14th, 2002 (registration number: 1839), prior to the study. Written informed consent was obtained from all participants.
Screening visit
At a screening visit, blood was drawn from all participants in the fasting state for measurements of standard hematologic and clinical chemistry parameters to exclude subjects with anemia (hemoglobin <12 g/dL), an elevation in liver enzymes (alanine amino transferase, aspartate
GLP-2 Plasma Levels
During the exogenous administration of GLP-2 over 120 minutes in the fasting state, plasma levels of intact GLP-2 increased from 10 ± 2 pmol/L to steady-state concentrations of 208 ± 8 pmol/L (P < .001; Figure 1), whereas total GLP-2 levels were raised from 29 ± 6 pmol/L to steady-state levels of 430 ± 17 pmol/L (P < .001; Figure 1).
Following test meal ingestion, total GLP-2 plasma concentrations increased from 17 ± 2 pmol/L to 27 ± 1 pmol/L during placebo administration (P < .001; Figure 2).
Discussion
The present studies were undertaken to investigate the effects of GLP-2 on endocrine pancreatic secretion and postprandial lipid concentrations, as well as on gastric emptying and acid secretion. We report an ∼40%–50% increase in glucagon concentrations, a higher rise in postprandial triglyceride and free fatty acid levels, and an ∼15% reduction in pentagastrin-stimulated gastric acid secretion, whereas insulin plasma concentrations and gastric emptying were virtually unaffected.
The fact that
References (55)
- et al.
Secretion of the intestinotropic hormone glucagon-like peptide 2 is differentially regulated by nutrients in humans
Gastroenterology
(1999) - et al.
Structure, measurement, and secretion of human glucagon-like peptide-2
Peptides
(2000) Glucagon-like peptide 1 (GLP-1)an intestinal hormone, signalling nutritional abundance, with an unusual therapeutic potential
Trends Endocrinol Metab
(1999)- et al.
Glucagon-like peptide 2 improves intestinal wound healing through induction of epithelial cell migration in vitro—evidence for a TGF-β-mediated effect
Regul Pept
(2004) - et al.
Glucagon-like peptide 2 improves nutrient absorption and nutritional status in short-bowel patients with no colon
Gastroenterology
(2001) - et al.
Glucagon-like peptide-1 [7-36]a physiological incretin in man
Lancet
(1987) - et al.
Effect of glucagon-like peptide-1 (proglucagon 78-107amide) on hepatic glucose production in healthy man
Metabolism
(1994) - et al.
Peripheral administration of GLP-2 to humans has no effect on gastric emptying or satiety
Regul Pept
(2003) - et al.
Structure, measurement, and secretion of human glucagon-like peptide-2
Peptides
(2000) - et al.
Glycerol-like contamination of commercial blood sampling tubes
J Lipid Res
(1971)
Measurement of gastric emptying rate of solid meals by means of a carbon-labeled octanoic acid breath test
Gastroenterology
GLP-2-mediated up-regulation of intestinal blood flow and glucose uptake is nitric oxide-dependent in TPN-fed piglets 1
Gastroenterology
Gastric secretory and humoral responses to anticipated feeding in five men
Gastroenterology
Gastrin
Best Res Pract Clin Endocrinol Metab
Effects of glucagon on postprandial carbohydrate metabolism in nondiabetic humans
Metabolism
Radio-immunoassays for glucagon-like peptides 1 and 2 (GLP-1 and GLP-2)
Scand J Clin Lab Invest
Glucagon-like peptide 1 but not glucagon-like peptide 2 stimulates insulin release from isolated rat pancreatic islets
Diabetologia
Enhancing incretin action for the treatment of type 2 diabetes
Diabetes Care
The potential role of glucagon-like peptide 1 in diabetes
Curr Opin Investig Drugs
Induction of intestinal epithelial proliferation by glucagon-like peptide 2
Proc Natl Acad Sci U S A
GLP-2 stimulates intestinal growth in premature TPN-fed pigs by suppressing proteolysis and apoptosis
Am J Physiol Gastrointest Liver Physiol
GLP-2 has differential effects on small intestine growth and function in fetal and neonatal pigs
Am J Physiol Regul Integr Comp Physiol
Human [Gly2] GLP-2 reduces the severity of colonic injury in a murine model of experimental colitis
Am J Physiol
Short-term administration of glucagon-like peptide-2. Effects on bone mineral density and markers of bone turnover in short-bowel patients with no colon
Scand J Gastroenterol
In vivo and in vitro degradation of glucagon-like peptide-2 in humans
J Clin Endocrinol Metab
Teduglutide (ALX-0600), a dipeptidyl peptidase IV resistant glucagon-like peptide 2 analogue, improves intestinal function in short bowel syndrome patients
Gut
Additive insulinotropic effects of exogenous synthetic human gastric inhibitory polypeptide and glucagon-like peptide-1-(7-36) amide infused at near-physiological insulinotropic hormone and glucose concentrations
J Clin Endocrinol Metab
Cited by (212)
Role of apolipoproteins in the pathogenesis of obesity
2023, Clinica Chimica ActaLong-acting agonists of human and rodent GLP-2 receptors for studies of the physiology and pharmacological potential of the GLP-2 system
2023, Biomedicine and PharmacotherapyPeptides in the regulation of glucagon secretion
2022, PeptidesThe Physiology and Pharmacology of Diabetic Gastropathy Management
2022, Comprehensive PharmacologyGlucagon-like peptide-2
2021, Handbook of Hormones: Comparative Endocrinology for Basic and Clinical Research
Supported by Deutsche Forschungsgemeinschaft (Me 2096/2-1), Wilhelm-Sander-Stiftung (grant no. 2002.025.1; to J.J.M.), and Deutsche Diabetesgesellschaft (DDG; to J.J.M.).